Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 28 Sept, 12:52 UTC

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

science

Sources

• T2Merck, Daiichi end plans to seek speedy approval of lung cancer ADCBioPharma Dive / Healthcare Dive / MedTech Dive28 Sept, 12:52